Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares after opening at $6.36 moved to $6.43 on last trade day and at the end of the day closed at $6.10. Company price to sales ratio in past twelve months was calculated as 16.39 and price to cash ratio as 6.01. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -0.81%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 12.69% to $3.64. The company on Mar. 26 said that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares fell -9.89% in last trading session and ended the day on $3.28. INO return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) yearly performance is 446.67%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares increased 13.41% to $4.40. The company on Mar. 28 announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved up 17.78% in last trading session and was closed at $4.57 while trading in range of $4.22 – $4.80 – Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -1.30%.
Morgan Stanley initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued on Wednesday, StockRatingsNetwork reports. The firm set an “equal weight” rating and a $75.00 price target on the stock. Morgan Stanley’s target price would indicate a potential upside of 5.03% from the company’s current price. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is -4.88%. On last trading day company shares ended up $68.55. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -13.85%. Analysts mean target price for the company is $100.17.
Leave a Reply